Other

Baxter International Inc.

Dade Behring Inc.

Abraxis Bioscience, LLC

Baxter Diagnostics Inc.

Applied Bioresearch, Inc.

Epiomed Therapeutics, Inc.

Dade Interantional Inc.

Ernest H Pfadenhauer

David Reed Helton

David Brian Fick

William A Stark

Jason Paul Sharp

Jun Ho Yang

Robert A Settineri

Catherine T Lee

James Lucot

Thomas J Hunter

Tan Thanh Dinh

A method of treating exposure to organophosphate agents and preventing morbidity due to such exposure through the administration of a triptan compound to a subject.

Treatment of organophosphate exposure with triptans

A method of treating exposure to organophosphate agents and preventing morbidity due to such exposure through the administration of a pyrazolopyrimidine compound such as ocinaplon, zaleplon, indiplon, or divaplon.

Treatment of organophosphate exposure with ocinaplon

Described herein is a method of delivering drugs to the blood stream directly by absorption through cell membranes in the wall of the rectum from a rectal suppository comprising a glyceride based excipient More specifically, CaNaEDTA is delivered rectally from a suppository containing water soluble, glyceride based excipient/carrier.

Chelation suppository for improved drug delivery

A screening method for identifying compounds with anti-emetic properties by evaluating binding affinity and efficacy of the compounds with respect to the 5-HT, 5-HT, and 5-HTreceptors.

Assay for determination of compounds having anti-emetic activity

Compositions comprising tetrahydroindolone derivatives in which the tetrahydroindolone moiety is covalently linked to a substituted arylpiperazine moiety and methods for treating neurological and psychiatric conditions using such compositions are disclosed.

Tetrahydroindolone derivatives for treatment of neurological conditions

Tetrahydroindolone derivatives for treament of neurological conditions

A method for preparing collagenous biological tissues for use as implantable bioprosthetic material, and articles prepared thereby. The method generally comprises the steps of a) contacting the tissue with an aldehyde fixative to effect cross-linking of the connective tissue protein(s) and subsequently b) contacting the tissue with a polyglycidyl ether. The treatment of the crosslinked tissue with the polyglycidyl ether serves to mitigate the tissue's propensity to undergo calcification following implantation in the body.

Method for inhibiting calcification of aldehyde-fixed bioprosthetic

The present invention provides methods for detecting the presence of or determining the amount of a ligand in a fluid sample. The methods comprise providing a first reagent comprising a sol particle having a detectable physical property bound to the ligand or ligand analogue (in a competitive format) or a substance capable of specifically coupling with the ligand (in a sandwich format), providing a second reagent having a detectable physical property comprising a sol particle bound to a substance capable of specifically coupling with the ligand and/or ligand analogue, if present, combining the first reagent, second reagent and the fluid sample and detecting before, during or after the reaction, a change in the physical property of the sol particles, which provides a qualitative or quantitative indication of the ligand in the fluid sample. The reagents couple with one another as a function of the presence of the ligand in the sample to thereby produce a change in the physical property of the sol particles which is related to the degree of coupling of the reagents. The invention also provides a kit for detecting the presence of or determining the amount of a ligand in a fluid sample. The invention further provides immunological complexes having a detectable physical property.

Homogeneous sol-sol assay

The invention disclosed is a sealed fluent material container having a chamber with an opening provided with a manually operable primary closure mechanism and a secondary closure mechanism that may be operated either manually or automatically. Manual removal of the primary closure mechanism from the chamber opening allows the secondary closure mechanism to extend a laterally moveable tongue from a horizontal guide recess on the top of the container to a normally closed position covering the opening. An engagable tab on the secondary closure permits the retraction of the moveable tongue against the biasing means to expose the chamber opening. The container has particular utility for use in automated chemical dispensers, analyzers and related equipment for the analysis and testing of blood, physiological fluids and other biological samples.

Growing community of inventors

Costa Mesa, CA, United States of America

Ernest H Pfadenhauer